Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Hu, Zhang Zhi ^a,b   Kagan, Benjamin L ^a   Ariazi, Eric A ^c   Rosenthal, Dean S ^a   Zhang, Lihua ^a   Li, Jordan V ^a   Huang, Hongzhan ^b   Wu, Cathy ^b   Jordan, V Craig ^a   Riegel, Anna T ^a   Wellstein, Anton ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ESTRADIOL; ESTROGEN; G PROTEIN COUPLED RECEPTOR; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; STEROID RECEPTOR COACTIVATOR 3; WNT PROTEIN; NCOA3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; TRANSCRIPTION REGULATION; BREAST TUMOR; DRUG EFFECT; FEMALE; GENETICS; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

APOPTOSIS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; IMMUNOPRECIPITATION; MASS SPECTROMETRY; NUCLEAR RECEPTOR COACTIVATOR 3; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BINDING; PROTEOMICS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; WNT PROTEINS;

EID: 79959593177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020410     Document Type: Article

References (80)

1. Lippman ME, Bolan G, (1975) Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256: 592-593.
2. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 365: 1687-1717.
3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62.
4. Nicholson RI, Johnston SR, (2005) Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 93 (Suppl 1): S3-10.
5. Brauch H, Jordan VC, (2009) Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer 45: 2274-2283.
6. Fichtner I, Becker M, Zeisig R, Sommer A, (2004) In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance. Eur J Cancer 40: 845-851.
7. Ariazi EA, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, et al. (2006) Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. The Journal of Steroid Biochemistry and Molecular Biology 102: 128-138.
8. Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, et al. (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116.
9. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, et al. (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302: 774-780.
10. Dodds EC, Goldberg L, Lawson W, Robinson R, (1938) Estrogenic activity of certain synthetic compounds. Nature 141: 247-248.
11. Haddow A, Watkinson J, Paterson E, (1944) Influence of synthetic oestrogens upon advanced malignant disease. BMJ 2: 393-398.
12. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, et al. (1977) Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237: 2079-2078.
13. Jordan VC, Lewis JS, Osipo C, Cheng D, (2005) The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast 14: 624-630.
14. Song RX, Mor G, Naftolin F, McPherson RA, Song J, et al. (2001) Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723.
15. Jordan VC, Ford LG, (2011) Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A "New" Biology of Estrogen-Induced Apoptosis. Cancer prevention research (Philadelphia, Pa).
16. Macedo LF, Sabnis G, Brodie A, (2009) Aromatase inhibitors and breast cancer. Ann N Y Acad Sci 1155: 162-173.
17. Musgrove EA, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
18. Arpino G, Wiechmann L, Osborne C, Schiff R, (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233.
19. Lahusen T, Henke R, Kagan B, Wellstein A, Riegel A, (2009) The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Research and Treatment 116: 225-237.
20. Zhao W, Zhang Q, Kang X, Jin S, Lou C, (2009) AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. Biochem Biophys Res Commun 380: 699-704.
21. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361.
22. Schiff R, Massarweh S, Shou J, Osborne CK, (2003) Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9: 447S-454S.
23. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, et al. (2001) Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276: 23763-23768.
24. Font de Mora J, Brown M, (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041-5047.
25. Oh A, List HJ, Reiter R, Mani A, Zhang Y, et al. (2004) The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 64: 8299-8308.
26. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai MJ, (2003) Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23: 7742-7755.
27. Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT, (2007) Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res 67: 7256-7265.
28. Coste A, Antal M, Chan S, Kastner P, Mark M, et al. (2006) Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J 25: 2453-2464.
29. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, et al. (2000) The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci U S A 97: 6379-6384.
30. Fereshteh MP, Tilli MT, Kim SE, Xu J, O'Malley BW, et al. (2008) The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 68: 3697-3706.
31. Torres-Arzayus MI, De Mora JF, Yuan J, Vazquez F, Bronson R, et al. (2004) High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6: 263-274.
32. Torres-Arzayus MI, Yuan J, DellaGatta JL, Lane H, Kung AL, et al. (2006) Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Cancer Res 66: 11381-11388.
33. Tilli MT, Reiter R, Oh AS, Henke RT, McDonnell K, et al. (2005) Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. Mol Endocrinol 19: 644-656.
34. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT, (2009) The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 116: 225-237.
35. Xu J, Wu R-C, O'Malley BW, (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9: 615-630.
36. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
37. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968.
38. Lewis JS, Osipo C, Meeke K, Jordan VC, (2005) Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94: 131-141.
39. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, et al. (2005) Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759.
40. Jordan VC, Lewis-Wambi J, Kim H, Cunliffe H, Ariazi E, et al. (2007) Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast 16 (Suppl 2): S105-113.
41. Bell AW, Deutsch EW, Au CE, Kearney RE, Beavis R, et al. (2009) A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods 6: 423-430.
42. Aebersold R, (2009) A stress test for mass spectrometry-based proteomics. Nat Methods 6: 411-412.
43. Hu Z-Z, Huang H, Wu CH, Jung M, Dritschilo A, et al. (2011) Omics-based molecular target and biomarker identification. Methods Mol Biol 719: 547-571.
44. Louet JF, Coste A, Amazit L, Tannour-Louet M, Wu RC, et al. (2006) Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program. Proc Natl Acad Sci U S A 103: 17868-17873.
45. Coste A, Louet JF, Lagouge M, Lerin C, Antal MC, et al. (2008) The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. Proc Natl Acad Sci U S A 105: 17187-17192.
46. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, et al. (2000) The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 97: 6379-6384.
47. Long W, Yi P, Amazit L, Lamarca HL, Ashcroft F, et al. (2010) SRC-3Delta4 Mediates the Interaction of EGFR with FAK to Promote Cell Migration. Molecular Cell 37: 321-332.
48. Deng Q, Huang S, (2004) PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 23: 4903-4910.
49. Brinkmeier ML, Potok MA, Cha KB, Gridley T, Stifani S, et al. (2003) TCF and Groucho-related genes influence pituitary growth and development. Mol Endocrinol 17: 2152-2161.
50. Nagahama Y, Ishimaru M, Osaki M, Inoue T, Maeda A, et al. (2008) Apoptotic pathway induced by transduction of RUNX3 in the human gastric carcinoma cell line MKN-1. Cancer Sci 99: 23-30.
51. Tong DD, Jiang Y, Li M, Kong D, Meng XN, et al. (2009) RUNX3 inhibits cell proliferation and induces apoptosis by TGF-beta-dependent and-independent mechanisms in human colon carcinoma cells. Pathobiology 76: 163-169.
52. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, et al. (2009) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27: 542-549.
53. Ahn J, Byeon IJ, Byeon CH, Gronenborn AM, (2009) Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J Biol Chem 284: 13812-13822.
54. Liu ZJ, Cai Y, Hou L, Gao X, Xin HM, et al. (2008) Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest 26: 878-882.
55. Sullivan A, Lu X, (2007) ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer 96: 196-200.
56. Zhao Y, Goto K, Saitoh M, Yanase T, Nomura M, et al. (2002) Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment. Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor. J Biol Chem 277: 30031-30039.
57. Lanz RB, Bulynko Y, Malovannaya A, Labhart P, Wang L, et al. (2010) Global characterization of transcriptional impact of the SRC-3 coregulator. Mol Endocrinol 24: 859-872.
58. Jordan JD, Carey KD, Stork PJ, Iyengar R, (1999) Modulation of rap activity by direct interaction of Galpha(o) with Rap1 GTPase-activating protein. J Biol Chem 274: 21507-21510.
59. Zhang J, Liu J, Yu C, Lin A, (2005) BAD Ser128 is not phosphorylated by c-Jun NH2-terminal kinase for promoting apoptosis. Cancer Res 65: 8372-8378.
60. Klumpp S, Krieglstein J, (2002) Serine/threonine protein phosphatases in apoptosis. Curr Opin Pharmacol 2: 458-462.
61. Fernando RI, Wimalasena J, (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15: 3266-3284.
62. Roux PP, Richards SA, Blenis J, (2003) Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol 23: 4796-4804.
63. Bundy DL, McKeithan TW, (1997) Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA. J Biol Chem 272: 33132-33139.
64. Mathas S, Johrens K, Joos S, Lietz A, Hummel F, et al. (2005) Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 106: 4287-4293.
65. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, et al. (2009) The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 106: 15732-15737.
66. Zimmer A, Reynolds K, (1994) Gene targeting constructs: effects of vector topology on co- expression efficiency of positive and negative selectable marker genes. Biochem Biophys Res Commun 201: 943-949.
67. Hoffman BG, Zavaglia B, Beach M, Helgason CD, (2008) Expression of Groucho/TLE proteins during pancreas development. BMC Dev Biol 8: 81.
68. Liu Y, Dehni G, Purcell KJ, Sokolow J, Carcangiu ML, et al. (1996) Epithelial expression and chromosomal location of human TLE genes: implications for notch signaling and neoplasia. Genomics 31: 58-64.
69. Cuevas IC, Slocum AL, Jun P, Costello JF, Bollen AW, et al. (2005) Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 65: 5070-5075.
70. Hiraike H, Wada-Hiraike O, Nakagawa S, Koyama S, Miyamoto Y, et al. (2010) Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer 102: 1061-1067.
71. Lewis-Wambi JS, Jordan VC, (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11: 206.
72. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, et al. (2004) Gadd45β mediates the NF-κB suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 6: 146-153.
73. Engelmann A, Speidel D, Bornkamm GW, Deppert W, Stocking C, (2008) Gadd45 beta is a pro-survival factor associated with stress-resistant tumors. Oncogene 27: 1429-1438.
74. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, et al. (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 70: 1184-1194.
75. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC, (1992) An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90: 77-86.
76. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
77. Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, et al. (2008) Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol Cell Biol 28: 6580-6593.
78. Hu Z-Z, Huang H, Cheema A, Jung M, Dritschilo A, et al. (2008) Integrated Bioinformatics for Radiation-Induced Pathway Analysis from Proteomics and Microarray Data. Journal of proteomics & bioinformatics 1: 47-60.
79. Han SJ, Jung SY, Malovannaya A, Kim T, Lanz RB, et al. (2006) A scoring system for the follow up study of nuclear receptor coactivator complexes. Nucl Recept Signal 4: e014.
80. Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, et al. (2007) IntAct-open source resource for molecular interaction data. Nucleic Acids Res 35: D561-565.